Titel
Optimizing VLP production in gene therapy: Opportunities and challenges for in silico modeling
Barbara Kraus
Biotherapeutics Process Development, Baxalta Innovations GmbH, a Part of Takeda Companies
... show all
Abstract
Over the past decades, virus-like particle (VLP)-based gene therapy (GT) evolved as a promising approach to cure inherited diseases or cancer. Tremendous costs due to inefficient production processes remain one of the key challenges despite considerable efforts to improve titers. This review aims to link genome-scale metabolic models (GSMMs) to cell lines used for VLP synthesis for the first time. We summarize recent advances and challenges of GSMMs for Chinese hamster ovary (CHO) cells and provide an overview of potential cell lines used in GT. Although GSMMs in CHO cells led to significant improvements in growth rates and recombinant protein (RP)-production, no GSMM has been established for VLP production so far. To facilitate the generation of GSMM for these cell lines we further provide an overview of existing omics data and the highest production titers so far reported.
Stichwort
gene therapygenome-scale metabolic modelHEK-293omicsvirus-like particle
Objekt-Typ
Sprache
Englisch [eng]
Persistent identifier
phaidra.univie.ac.at/o:2008536
Erschienen in
Titel
Biotechnology Journal
Band
18
Ausgabe
7
ISSN
1860-6768
Erscheinungsdatum
2023
Publication
Wiley
Erscheinungsdatum
2023
Zugänglichkeit
Rechte
Rechteangabe
© 2023 The Authors
Universität Wien | Universitätsring 1 | 1010 Wien | T
+43-1-4277-0